CARDIOVASCULAR & RENAL DRUGS ADVISORY COMMITTEE
August 10, 2001
TRACLEER (bosentan) in Pulmonary Arterial Hypertension
Briefing Information
Actelion Pharmaceuticals Ltd pdf
Disclaimer
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
FDA Briefing
Secondary Medical Review pdf htm
Medical Review of Safety and Efficacy Conclusions pdf htm
Medical Review of Safety pdf htm
Medical Review of Efficacy pdf htm
Statistical Review and Evaluation Amendment pdf htm
Statistical Review and Evaluation pdf htm
Overall Summary and Evaluation of Preclinical Pharamcodynamics, Toxicokinetics and Toxicology pdf htm
Biopharmaceutics Review pdf doc